Physician profile
Cheguevara I Afaneh
NPI 1205089463
$1,406,594.46
in general payments reported to CMS, 2019-2025
22 companies · $86K in 2025
The $86K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223K · 2020: $125K · 2021: $270K · 2022: $320K · 2023: $244K · 2024: $140K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $304K · Travel and Lodging: $67K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $34K · Food and Beverage: $9,871 · Honoraria: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $304,000.00 |
| Travel and Lodging | $66,931.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,000.00 |
| Consulting Fee | $34,157.50 |
| Food and Beverage | $9,870.65 |
| Honoraria | $520.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,107,271.19 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| W. L. Gore & Associates, INC. | $290,354.55 | 2019-2025 | Gore Synecor Biomaterial, Gore Enform Preperitoneal Biomaterial, Gore Bio-A Tissue Reinforcement |
| Ethicon INC. | $2,525.00 | 2021 | |
| Medical Device Business Services, INC. | $1,512.50 | 2024 | |
| Davol INC. | $1,511.08 | 2021-2025 | Phasix Mesh, Bard 3dmax Mesh, Arista |
| Ethicon US, LLC | $968.81 | 2024-2025 | Linx Reflux Management System, Harmonic, Echelon; Endopath |
| Asensus Surgical, INC. | $600.00 | 2022 | |
| Becton, Dickinson and Company | $543.00 | 2024-2025 | Phasix Mesh |
| Laborie Medical Technologies Corp. | $525.09 | 2024-2025 | Alphaone |
| Boston Scientific Corporation | $343.72 | 2020-2024 | Spyglass, Spyglass Discover |
| Celltrion USA INC. | $93.42 | 2024-2025 | Vegzelma |
| Abbvie INC. | $84.53 | 2024-2025 | |
| Tactile Systems Technology INC | $47.61 | 2020-2021 | |
| Lilly USA, LLC | $43.48 | 2023-2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $39.48 | 2024-2025 | Entyvio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $32.38 | 2023 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Conmed Corporation | $24.36 | 2024 | Airseal |
| Solventum Corporation | $22.94 | 2025 | V.A.C. Veraflo Cleanse Choice, Prevena, V.A.C. Granufoam |
| Astrazeneca Pharmaceuticals Lp | $20.96 | 2022 | |
| Shire North American Group INC | $15.82 | 2019 | |
| Teleflex LLC | $14.54 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheguevara Afaneh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.